TEMIS launches Luxid® for Life Sciences

TEMIS Text analytics solutions bring long-awaited answers to the challenge of knowledge discovery in the Life Sciences.

(PresseBox) ( Paris, France and Philadelphia, USA, )
TEMIS, a leading provider of Text Analytics, today introduced its first industry-specific edition of Luxid®, its recently launched Information Intelligence solution, serving the global information needs of Life Sciences Corporations.



Luxid® for Life Sciences meets the specific requirements of pharmaceutical, biotechnology, and medical device organizations:
- It helps Life Sciences Corporations increase their research effort effectiveness. In order to support scientists from R&D team to explore the ever growing scientific literature, Luxid® for Life Sciences offers advanced features dedicated to the analysis of the relations between biological, medical and chemical entities. It provides a set of navigation and discovery tools enabling scientists to evaluate the “druggability” of a target or to profile a chemical compound.
- Luxid® for Life Sciences also assists legal departments with increasing their IP assets protection while prior art analysis is becoming increasingly difficult. Luxid® for Life Sciences gathers multiple patent sources, extracts and normalizes key metadata (assignees, patent series …) together with relevant entities (genes, diseases, chemical compounds …). It allows patent lawyers to speed up patent portfolios analysis to better evaluate freedom-to-operate opportunities around promising chemical compounds and also to detect early signals of possible patent infringement.
- Finally, Luxid® for Life Sciences helps Marketing and Safety departments monitor adverse event related risks. Luxid® for Life Sciences automates adverse event detection, through the extraction of relevant links between drugs, treatments and induced pathologies or symptoms. It even provides a workflow of escalation rules to comply with the latest pharmacovigilance regulatory obligations.

”We built our first industry-specific edition of Luxid® to meet the requirements of our most demanding Life Sciences customers.”, said Eric Brégand, CEO of TEMIS. “This corporate-wide single entry-point solution brings to the Scientist a comprehensive set of advanced knowledge discovery features to unlock the value from commercial, public and corporate data sources.”

To ease customers’ deployments, Luxid® for Life Sciences has been structured into three stackable software applications:
1. Luxid® Annotation Factory performs the extraction of high value information from text. Its deep understanding of all major languages(1) powers the ability to reliably identify entities and relationships. In order to deliver the most accurate and targeted insight, Luxid® for Life Sciences natively embeds four exclusive Life Sciences annotators(2), based on TEMIS acclaimed Skill Cartridge™ technology.
2. Luxid® Information Mart is an easy-to-administrate platform that federates heterogeneous sources(3), and enriches the harvested documents, leveraging Luxid® Annotation Factory in order to build a knowledge base.
3. Luxid® Information Analytics is a web-based and feature-rich portal enabling information discovery on top of Luxid® Information Mart. Its innovative User Interface provides access to advanced search and filtering, document navigation, time analysis, cross-tab views, information mapping and clustering. The exclusive Knowledge Browser turns any document set into a navigable knowledge graph, displaying extracted entities semantic relationships. To enable collaborative discoveries, Luxid® Information Analytics also offers multiple-view dashboards through user-defined and shared Centers of Interest.

Luxid® for Life Sciences was designed from the ground up on UIMA(4), the new standard applicative framework for unstructured analytics, which was created by IBM. The UIMA standard provides the foundation for the next generation of information retrieval and analytics applications. UIMA based Luxid® for Life Sciences proves to be robust, massively scalable and able to power the most demanding Text Analytics applications.

The Luxid® for Life Sciences platform is also integrated with IBM OmniFind Enterprise Search to incorporate analytics into broader enterprise search and discovery applications.

Availability Information
Luxid® is available now. For more information, please visit www.temis.com or e-mail info@temis.com

- (1) Luxid® supports 20 languages: Czech, Dutch, English, French, German, Greek, Hungarian, Italian, Polish, Portuguese, Russian, Spanish - Arabic, Chinese, Japanese, Korean - Finnish, Swedish, Norwegian Bokmal and Danish.
- (2) TEMIS annotators for Life Sciences:
- Competitive Intelligence Life Sciences edition Annotator extracts critical information such as mergers and acquisitions, drugs clinical status, licensing agreements or FDA regulation approvals. It includes over 3000 companies’ names together with their joint-ventures and affiliates.
- Biological Entity Relationships Annotator extracts biological mechanisms (gene expressions, protein interactions, localization, etc.) from scientific or medical literature.
- Medical Entity Relationships Annotator targets information such as drug regulation, clinical trials, therapeutics, diagnostics and counter indications, combined with an exhaustive medical taxonomy.
- Chemical Entity Relationships Annotator identifies chemical compounds and reactions and translates extracted names into chemical structure.
- (3) Websites, press wires, blogs, scientific and patent databases, internal content.
- (4) UIMA: Unstructured Information Management Architecture. http://www.research.ibm.com/UIMA/)

- (1) Luxid® supports 20 languages: Czech, Dutch, English, French, German, Greek, Hungarian, Italian, Polish, Portuguese, Russian, Spanish - Arabic, Chinese, Japanese, Korean - Finnish, Swedish, Norwegian Bokmal and Danish.
- (2) TEMIS annotators for Life Sciences:
- Competitive Intelligence Life Sciences edition Annotator extracts critical information such as mergers and acquisitions, drugs clinical status, licensing agreements or FDA regulation approvals. It includes over 3000 companies’ names together with their joint-ventures and affiliates.
- Biological Entity Relationships Annotator extracts biological mechanisms (gene expressions, protein interactions, localization, etc.) from scientific or medical literature.
- Medical Entity Relationships Annotator targets information such as drug regulation, clinical trials, therapeutics, diagnostics and counter indications, combined with an exhaustive medical taxonomy.
- Chemical Entity Relationships Annotator identifies chemical compounds and reactions and translates extracted names into chemical structure.
- (3) Websites, press wires, blogs, scientific and patent databases, internal content.
- (4) UIMA: Unstructured Information Management Architecture. http://www.research.ibm.com/UIMA/)
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.